The following is a summary of the Cerus Corporation (CERS) Q1 2024 Earnings Call Transcript:

Financial Performance:

• Cerus reported Q1 2024 product revenue of $38.4 million, a 24% YoY growth, largely from strong North American platelet sales.

• Operating expenses declined by 12% to $34.3 million.

• The reported net loss attributed to Cerus for Q1 2024 narrowed by 38% to $9.7 million or $0.05 per share.

• The non-GAAP adjusted EBITDA loss totaled $2.7 million, an improvement from a loss of $9.8 million in Q1 2023.

• Cerus anticipates achieving its revenue guidance in the range of $172-$175 million for full-year 2024, including INTERCEPT Fibrinogen Complex (IFC) revenue between $8 million and $10 million.

Business Progress:

• Cerus disclosed positive top-line results from the Phase 3 ReCePI clinical trial for INTERCEPT red blood cells (RBCs).

• Significant commercial progress is seen with INTERCEPT in key markets such as the Middle East and North America.

• Canadian Blood Services has almost fully implemented INTERCEPT platelets across their network.

• Growing interest for INTERCEPT is reported in the Middle East, an area of planned expansion.

• Cerus has managed to overcome significant regulatory barriers like FDA approval and MDR clearance, and expects ongoing growth and investments in these regions.

• The company anticipates receiving a CE Mark under the MDR process by the end of this year to extend its reach.

More details: Cerus IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.